IJCNP, Volume 2, Issue 7, 2024 ISSN: 2995-536X
https://medicaljournals.eu/index.php/IJCNP

INTERNATIONAL JOURNAL OF COGNITIVE NEUROSCIENCE AND PSYCHOLOGY

OPTIMIZING THE USE OF MAGNESIUM SULFATE FOR MANAGING ACUTE ASTHMA IN PEDIATRIC PATIENTS

Ahmad Maher Al Sayeh, Waleed Mohammad
Al Hussein Bin Talal University, Nursing and Health Science College

Rahaf Jehad Al-jararha
Internship in the Ministry of health in Jordan

Rahaf Zeyad Albatayneh
Yarmouk University, Medicine College

ALIA' ABDALLAH ALKHATAYBEH
King Hussain Cancer Center

RASHA RAKAN AL KREASHA
General Physician at ministry of health in Jordan

Fernando Jesús Plaza Del Pin
Department of Nursing, Physiotherapy and Medicine. Faculty of Health Sciences, University of Almería

Abstract: Asthma is one of the most common chronic illnesses affecting children worldwide. It's marked by sudden episodes of wheezing, coughing, chest tightness, and difficulty breathing. Despite advancements in understanding and treating asthma, managing acute asthma attacks remains a major challenge in pediatric healthcare. Traditional treatments include short-acting beta-agonists, systemic corticosteroids, and oxygen therapy. Yet, these methods sometimes fall short, requiring additional measures. Magnesium sulfate (MgSO4) has emerged as a promising supplementary treatment due to its ability to relax muscles, reduce inflammation, and widen the airways. This paper reviews the effectiveness, safety, and best practices for using MgSO4 to manage acute asthma in children.

The literature reveals that MgSO4 works by blocking the calcium pathways that cause airway constriction, thus helping to open the airways and reduce inflammation. Numerous studies, including randomized controlled trials and observational research, have shown that MgSO4 can improve lung function, reduce hospital admissions, and lessen the need for extra bronchodilator treatments. However, there's still no clear agreement on the best doses, methods of administration, and criteria for selecting patients.

Key findings show that both intravenous and nebulized MgSO4 are effective for acute asthma. Research indicates that MgSO4 can quickly improve lung function and correct oxygen levels. Despite these benefits, there's a risk of side effects, like low blood pressure and electrolyte imbalances, which means careful monitoring and tailored dosing are essential.

This paper also highlights gaps in current research, especially concerning the safety and long-term effects of MgSO4. It emphasizes the need for further studies to refine dosing protocols and develop comprehensive guidelines for its use in pediatric asthma care. Personalized treatment plans that consider factors such as the child's age, severity of asthma, and other health conditions are crucial for optimizing MgSO4 therapy.

Research methodology includes a systematic review of existing literature and prospective cohort studies to evaluate various dosing protocols and their outcomes. We'll collect data on demographics,

clinical characteristics, and treatment responses, using statistical analysis to compare the effectiveness and safety of different protocols. This approach aims to provide evidence-based recommendations for healthcare providers, enhancing the management of acute asthma in children.

Conclusion, optimizing MgSO4 use in pediatric asthma management has great potential to improve clinical outcomes and reduce healthcare burdens. This review underscores the need for standardized treatment guidelines and further research to ensure the safe and effective use of MgSO4, ultimately benefiting children's health and healthcare systems.

Key words: Asthma, Pediatric, Magnesium Sulfate, Acute Exacerbation, Bronchodilator, Anti-inflammatory, Treatment Optimization, Clinical Guidelines.

Introduction

One of the common major problems among children all over the world is asthma[1]Tesse. It is a chronic airway inflammation problem that often presents symptoms starting from episodic wheezing, coughing, tightness in the chest, and dyspnea. At present, among the chronic diseases present in childhood, asthma shows the highest rates of prevalence, ranging around 339 million people throughout the world[2] Asher.Although our knowledge base and understanding of the underlying physiology of asthma and its treatments have increased, it still remains one of the biggest challenges in the management of children's healthcare, often needing immediate action to avert grave sequela.[3]Sullivan

That makes effective and efficient therapeutic interventions very important to reduce symptoms, improve lung function, and avert serious respiratory problems within controlling and managing those urgent asthmatic attacks. Main treatments include short-acting beta-agonists, systemic corticosteroids, and oxygen therapy. The therapies become necessary for some children, therefore, because the usual treatment is not sufficient enough for them to gain some progress.

Magnesium sulfate (MgSO4) is another promising adjuvant, as it elicits bronchodilatory, anti-inflammatory, and muscle relaxant activities. This is through the blockade of calcium-mediated bronchoconstriction, which may have potential over the airway dilation, thus improving respiration. Magnesium sulfate may also help control airway inflammation and reduce the release of inflammation mediators in the context of asthma.

The best practice guidelines in the use of magnesium sulfate for pediatric asthma treatment still remain to be established, despite being a promising medication[4] [5](Hughes, Amantéa). Further important issues are the development of optimal dose, route, and the identification of susceptible children. In addition, such drug therapy requires monitoring and assessing the risks of possible side effects, such as an imbalance in electrolytes and muscle weakness.

To fill these research gaps and further improve the use of magnesium sulfate in the treatment of children with severe asthma attacks, this proposal is intended to reach its goal. By critically appraising literature, including controlled trials and observational studies, we aim to try and bring out how effectively and safely magnesium sulfate works more precisely and come up with guidelines in its use. We will also investigate which are the children most likely to respond more positively to the treatment and develop tailored treatments for them, thereby improving asthma care among children and preventing morbidity due to asthma.

Background

Asthma exacerbations contribute to a large part of the burden on the children's healthcare system while, at the same time, they affect a vast percentage of emergency department visits and hospital admissions[1]Tesse. Though much advancement has been witnessed in disease-related treatment approaches, yet this still heads among the top few most common chronic conditions prevalent amongst children globally. The management of an acute asthma attack in pediatric patients usually entails inhaled bronchodilators with systemic corticosteroids as the first-line therapy, aimed at relief of

bronchoconstriction and decreasing airway inflammation. The role of magnesium sulfate as a part of adjuvant therapy in the management of acute exacerbations of asthma in children, however, has been the focus of much more recent attention.

Magnesium is an essential mineral that has been implicated in a variety of physiological processes, including the regulation of smooth muscle function.

Magnesium sulfate, a frequently used magnesium preparation, has been established to possess strong bronchodilatory properties against the mechanism responsible for the characteristic feature of asthma attacks. In addition to these, magnesium has an anti-inflammatory impact, which, if added to other effects, may further enhance protection against bronchoconstriction in the present state and could decrease airway inflammation overall[6] [7](Cheuk, Griffiths) . Many studies have found if magnesium sulfate is an effective and safe therapy when used Griffiths et al. (2020) [7] concluded through the meta-analysis that magnesium sulfate administration was associated with significantly improved lung function and reduced admissions in the hospital among pediatric asthma patients.

Similarly, Jones et al. (2021) [9] reported that a systematic review had outlined the potential benefits of magnesium sulfate in reducing the requirements for additional bronchodilator therapy and shortening the duration of hospital stay in children experiencing severe asthma exacerbations. Despite the optimistic results, the best dosage regimens, safety profiles, and selection criteria in patients for this therapy are continuing subject areas of research.

This is still justified to further explore and develop more evidence-based practice guidelines from the variety of designs used in studies, the populations of patients involved, and the outcome measures used in different investigations on the use of magnesium sulfate in this context. More recently, the adjunctive role in the same population has been explored for agents such as intravenous magnesium sulfate. By way of illustration, one randomized controlled trial by Smith et al. (2023) had found that the use of intravenous magnesium sulfate was of more benefit in the case of children with severe asthma exacerbation, refractory to standard therapy with bronchodilators and corticosteroids. These findings identify the patient populations most likely to benefit from adjunctive magnesium sulfate therapy.

In summary, it means that magnesium sulfate therapy is promising for the adjunctive management of acute exacerbations of asthma in children. It may be an agent of considerable value to add to the traditional regimen during exacerbations of pediatric asthma, through bronchodilatory and anti-inflammatory actions. Future research may define dosing strategies, safety profiles, and patient selection criteria that will allow for optimized therapeutic benefit by magnesium sulfate in this population at a minimum. This, in turn, permits a wider perspective of the current role of magnesium sulfate in the management of pediatric asthma and the framing of optimized approaches to treatment with improved clinical outcomes in children who are faced with acute exacerbations of this disease.

Research Objectives

This paper review project has an overall objective of optimizing the use of magnesium sulfate in managing the acute asthmatic condition in pediatric patients by:

1. Review of literature already available on the use of magnesium sulphate in the management of pediatric acute asthma, keeping in mind these objectives in order to identify gaps in literature and areas where further research is needed.
2. Literature review on the safety and effectiveness of magnesium sulfate in the pediatric population, with special reference to possible side effects and outcomes.
3. Assess different dosing protocols to finally decode the most effective and safe regimen for the administration of magnesium sulfate.
4. Patient-specific factors that need to be checked to know the response to magnesium sulfate therapy include age, severity of asthma, and co-morbidities.

5. Formulating evidence-based recommendations for the use of magnesium sulfate in pediatric acute asthma management.

Significance

The significance of the use of magnesium sulfate in treatment in pediatric asthma is therefore of immense value to clinical practice, either in terms of a change in the procedure or as a potential change agent in relation to patient outcomes and, by implication, costs of care. Other derived benefits include finding the right effective dosing of magnesium sulfate and addressing safety concerns, besides customizing treatment plans per individual needs. **First**, finding the right dose for magnesium sulfate in order to enhance effectiveness in treatment is imperative. It also allows the doctors to understand how varying doses can affect outcome, hence striking the right balance in benefits and potential side effects, adding more precision to pediatric asthma treatment. **Second**, an understanding of the risks for safety associated with magnesium sulfate is very important. This will assist the health provider to make a safer choice of treatment, viewing the probable adverse effects in relation to the benefit, hence enhancing patient safety. **Third**, adapting treatment plans to every patient emphasizes the relevance of offering personalized care. This is quite a deviation from the routine treatment that assures much better outcomes and, for sure, puts satisfaction among the patients. This altogether goes a long way in the management of pediatric asthma and heralds a new dawn of better care. These optimization efforts bear fruits not only in terms of the clinical impacts but also with respect to healthcare economics. These will have the potential of being key factors of cost control in healthcare, increasing treatment efficacy while diminishing complications. The above will also add to cost-effectiveness, proper use of resources, and decrease the ratio of the health systems' savings and the economic burden for pediatric asthma care. Therefore, the character of this study is applied since it has practical purposes and goes beyond academic interest: to put forward recommendations to health practitioners. This helps to broaden the knowledge of how to manage pediatric asthma, offering the practitioner information that will help them take action to manage the disease effectively and confidently. The above progress holds more promises for a better future for children with severe asthma attacks in the optimal use of magnesium sulfate, leading to better health outcomes and more sustainable health care through the synthesis of scientific research and clinical expertise.

Methodology

To generalize the objectives that have been outlined above, the project will be a type of comprehensive and systematic approach that combines literature review and original research. The methodological structure will be based on the following steps:

Literature Review

Literature on the current subject will be searched systematically to glean insight regarding the use of magnesium sulfate in the management of pediatric asthma exacerbations. Searching will be performed through databases like PubMed, Scopus, and Web of Science. The search will include the words "magnesium sulfate," possibly in combination with other terms regarding "pediatric asthma" and "acute exacerbations." Articles that will be included are exclusively randomized control trials, cohort studies, case-control studies, and systematic reviews. Emphasis will be given to safety outcome data, measures of efficacy, dosing regimens, and how patient characteristics may influence the latter.

Research Design

This kind of design would be carried out to fill up the identified gaps within the review of literature. The review that is going to be formulated is a prospective cohort study designed to assess the response in pediatric patients presenting with acute exacerbations of asthma to the emergency department who receive various dosing protocols of magnesium sulfate.

Participant Selection

Pediatric patients presenting with an acute asthma exacerbation for their enrollment after informed consent from guardians or legally acceptable representatives. Inclusion criteria will include age parameters and an established diagnosis of asthma confirmed by set clinical criteria.

Intervention

The study will involve varying dosing protocols of magnesium sulfate in its dosage and administration routes. Dose regimens will be guided by available literature and expert recommendations, although allowances will be made for variations due to patient age and severity of the asthma.

Data Collection

The collection of data needs to be prospective in nature. These would include the demographics and clinical characteristics of the patient at baseline, in addition to the details of the dosage of magnesium sulfate given. Outcome measures would include hospital admission rates, inpatient hospital days, change in pulmonary function, and adverse events.

Data Analysis

The statistical analysis to be identified will be the most efficient and safe protocol for dosing in different schemes of applying magnesium sulfate. The carried out comparative analyses allowed investigating the groups' differences in outcomes, while subgroups, being patient characteristics, were meant to identify potential predictors of treatment response.

Synthesis and Recommendations

The synthesized evidence from systematic literature review and original research findings shall form the basis for the recommendations about practicing with magnesium sulfate in the management of pediatric acute asthma. It will give recommendations for appropriate dosing regimens and patients' selection based on the best available evidence, considering strategies to minimize adverse events. This study aims to contribute improved understanding and optimization in the use of magnesium sulfate for managing pediatric patients presenting with an acute exacerbation of asthma. This research will have the aim of bettering the clinical practice and outcome evidence for children who have to face this challenge through evidence-based recommendations.

The following is a summary of the literature presented in the review regarding studies done to evaluate the efficacy and safety of adjunctive magnesium sulfate (MgSO4) in the management of acute asthma exacerbations among pediatric patients.

Study	Year	Sample Size	Age Range	Indication	Treatment	Dosing Route	Control	Inhaled B2 Agonist	Inhaled Anticholin-ergics	Systemic Corticosteroid	primary outcome
Özdemira [11]	2020	136	6–17 years	mild and moderate	40–50 mg/kg or maximum e1,500 mg (>30 kg) of single dose IV MgSO4, administered over 60 min	IV	none				improved pulmonary function tests in children
Aslan[12]	2023	129	(2-8) years	moderate to severe acute asthma attacks	one dose of nebulized magnesium sulfate (150 mg/doz) at 15 min intervals	Nebulized	none	three doses of nebulized 1.5 mg / 1.5 ml salbutamol		one dose of methylprednisolone (1 mg/kg)	faster correction of oxygen saturation
Daengsuwan [13]	2017	28		Severe	single dose of MgSO4	IV , nebulized	none	three doses of nebulized	nebulized ipratropium	intravenous corticoste	rapid clinical improve

					infusion (50 mg/kg) for over 20 minutes			salbutamol	bromide/ fenoterol (500 µg/dose)	roid	ment
Kokotajlo[14]	2014	53	18 years or younger	acute asthma exacerbations	25 to 100 mg/kg/dose3–7 over 20 or 35 minutes	IV	normal saline	Albuterol	ipratropium	systemic corticosteroids	intubation and / or PICU admission
Schuh[15]	2021	816	2 to 17 years	moderate to severe respiratory distress	40 to 75 mg/kg (maximum 2 g)over 20 minutes	IV	normal saline	nebulized albuterol (5 mg)	ipratropium bromide	systemic corticosteroids	hospitalization independent of asthma severity
DeSanti DO[16]	2018	516	2-18 years	status asthmaticus	25 to 75 mg/kg/dose (standard dose was 50 mg/kg/dose) with a maximum of 2000 mg/dose administered over 60 min	IV	none	albuterol 2.5 mg	ipratropium 0.5 mg	prednisolone 2 mg/kg oral loading dose with a maximum dose of 60 mg, prednisone 60 mg oral loading dose, or methylprednisolone 1 mg/kg IV loading dose with a maximum dose 120 mg	no shorter time on continuous albuterol, or hospital length of stay
MUSTAFA[17]	2018	100	5-12 years	acute exacerbation of asthma of less than 6 hours duration	3 ml (150mg)	Nebulized	normal saline	nebulization of SALBUTAMOL 3 times at 20 minutes			mean SPO2 was significantly higher in MgSO4 group as compared to placebo group.
Graff[18]	2019	313	2 to 18 years	status asthmaticus	50 to 70 mg/kg (max 2 gm) over 20 minutes	IV	none	nebulized albuterol	ipratropium bromide	systemic corticosteroids	higher incidence of diastolic hypotension in patients receiving concomitant Mg
Johnson[19]	2020	61 854 visits	2-17 years	acute asthma hospitalized or discharged from the ED	median dose: 49.5 mg/kg	IV	none	albuterol	inhaled ipratropium bromide	systemic corticosteroids	preventing hospitalization is limited
Schuh[20]	2020	5846	2 to 17 years	moderate or severe respiratory distress	600 mg (1.2 mL)	Nebulized	normal saline	inhaled albuterol (500-1000 µg/treatment)	ipratropium bromide (80 µg/treatment)	oral corticosteroid (ie, dexamethasone, 0.3-0.6	no significant decrease hospitalizations

										mg/kg/dose, maximum, 20 mg; or prednisolone, 1-2 mg/kg/dose, maximum, 60 mg)	within 24 hours compared with placebo
Wongwaree[21]	2022	40	2-15 years	Moderate to severe asthma	50% MgSO4 0.3 ml (150 mg) was diluted in sterile water 2.2 ml	Nebulized	none	nebulized salbutamol	ipratropium bromide	Hydrocortisone (5 mg/kg/dose) IV q 6 hr	rapid decrease in the severity of asthma attack
Ehsan[22]	2023	280	2- 12 years	acute severe asthma	50% solution of 50 mg/kg in 30 ml 0.18% saline in D5W over 20 minutes	IV	none				improvement of respiratory symptoms
Kapuscinski[23]	2020	211	2 years to 18 years	asthma exacerbation	>27 mg/kg	IV	none	albuterol	ipratropium	systemic corticosteroids	increased need for invasive or non-invasive mechanical ventilation
					<27 mg/kg						
DeLaroche[24]	2021	285	5–11 years	asthma exacerbation	25 and 75 mg/kg	IV	none	albuterol	ipratropium	systemic corticosteroids	improved ED throughput without increasing return ED visits or hospitalizations for asthma.
Abdul Aziz[25]	2023	110	6-15 years	acute asthma through (ER) CRS >5	25-75 mg/kg over 30 min with blood pressure monitoring	IV		continuous salbutamol nebulization (0.15-0.5 mg/kg/h),		intravenous methylprednisolone 2 mg/kg	administration of IV MgSO4 (within 24 hours) is beneficial and results in fewer admissions to PICU and reduces the mean number of days spent on oxygen therapy
Siddiqui[26]	2022	85	6-14	signs and symptom	inhaled magnesiu	inhaled		salbutamol (5 mg)			The addition

				s of acute exacerbation of bronchial asthma if they had been previously diagnosed and treated for bronchial asthma or history and examination findings were suggestive of bronchial asthma based on paediatric asthma severity score admitted in PICU	m sulphate (95 mg)			or inhaled salbutamol (5 mg) alone.			of nebulized MgSO4 to salbutamol does not seem to result in improvement in lung function in the management of acute asthma in Indian children
Abbreviations: IV, intravenous, PRAM, preschool respiratory assessment measure, PICU, pediatric intensive care unit, CRS clinical respiratory score											

Furthermore, key findings, trends, and limitations among the diversity of reviewed studies will become clear, thus painting a wide landscape of MgSO4 use in pediatric asthma care.

Study Characteristics

The studies reviewed span one decade, from 2014 through to 2023, hence a sustained interest in the exploration of MgSO4 as a therapeutic option for pediatric asthma exacerbations. The sample sizes varied from quite small studies to the very small ones, a mirroring of heterogeneity of study designs, settings, but also different conditions.

Treatment Modalities

Others investigated administration routes and regimens of MgSO4, between IV infusion to nebulized formulations. With dosing protocols that start from single dose, weight-based administrations to those that are administered several times at a time interval. Notably, the dosages have been highly variable across all the studies, from weight-based to fixed doses.

Efficacy Outcomes

However, the major outcome efficacy in different studies had been targeted at an improvement in pulmonary function, oxygen saturation levels, and clinical symptomatology. The findings from the reviewed studies have shown that the administration of MgSO4 in whatever mode of delivery is related to favorable outcomes that include enhanced pulmonary function and faster correction of oxygen saturation and rapid clinical improvement.

Safety Considerations

While MgSO4 holds a promising beneficial effect, concerns on its safety cannot be overstated. Studies have revealed that the rate of adverse events, including diastolic hypotension, electrolyte imbalance, muscle weakness, is at variance, and this generally occurs at high doses[27]. Its adverse reaction seems to be dose-related and thus needs titration and monitoring to avert it.

Variability in Study Findings:

In addition, while most showed an improving trend in general, variability was still evident from one study to another. Most signaled strong improvement of clinical outcomes post-administration of MgSO4, and the relative effectiveness it pointed to was for hospitalization rates and symptom resolution. These could be the difference in patient population, severity of asthmatic exacerbations, and treatment protocols.

Factors Influencing Treatment Response

Further, the magnitude of response to the treatment with MgSO4 therapy is influenced by the interaction of different factors, namely, age of the patient, severity of asthma exacerbation, and the presence of other comorbidities. This points to the possibility of an individual or personalized kind of treatment where greater benefit was seen in younger and severely exacerbated patients with MgSO4 adjuvant therapy.[28] Rovsing

Implications for Clinical Practice

The reviewed literature shows MgSO4 as a possible adjunct in the management of pediatric asthma. The referral of further studies is in fact required for the purpose of refining an optimum dosing regimen, route of administration, and patient selection criteria.

Furthermore, due care to the safety profile and protocol of monitoring will be paramount to put in place MgSO4 use without serious adverse events.

Data Processing and Statistical Analysis

This paper analyzes the effectiveness, safety, and best dosing protocols for using MgSO4 based on data collected from literature and original studies. The following are statistical techniques and analysis.

Study Characteristics and Data Sources

Thus, being conducted from 2014 to 2023, its specimens can reflect the entire scope of the rare already studies and recurrent extensive cohort evaluation. It has data differing by the types of therapies, schedules, and populations, which are grounds for further vivid statistical processing. Finally, about the different studies, the primary outcomes measured are a visible enhancement of pulmonary functioning, oxygenation saturation, beneficial rate of preventional hospital admissions, and adverse effects.

Descriptive Statistics

Patient or Population Sample: Aggregates the size of the sample amongst all the studies. The measurements showing how age is distributed include both central tendency and dispersion by the mean, median, standard deviation, and range. Gender Distribution is being analyzed; results of these are raw frequency counts and percentages. Treatment Modalities and Dosing Protocols Frequency of the various treatment modalities [IV vs nebulized MgSO4]. Reports of approximate dosage and average dose of study application dosages.

Inferential Statistics

MgSO4 efficacy: Better Lung Function: The pretreatment and post-treatment values were compared using the paired t-test or Wilcoxon signed-rank test for skewed data when comparing the pulmonary metrics. This can be applied to using fixed-effects or random-effects models, which synthesize the findings from various studies by serving as the standard metric along which the effect is pooled. Oxygen saturation levels: Oxygenation improvement in variable dosing groups is statistically compared by ANOVA or Kruskal-Wallis tests. The forest plot presents the effect sizes of various studies, including respective confidence intervals. Safety and Adverse Events: Adverse Event Rates: Chi-square testing or Fisher exact testing with small sample results has been carried out to compare the incidence of adverse events in the treatment and control groups. Although the predictors of this adverse event have been primarily determined using logistic regression models, some confounding may still

happen, especially from age or severity of asthma. Specifically Stratified analysis by the stratification of age, severity of asthma, and other co-morbidities.

Interaction terms are included in regression models because they enable an examination of whether there is a differential treatment effect across the prespecified subgroups.

Function Integration and Data Analysis

Efficacy Out, these results shall be presented in summary tables and forest plots with a summary of the estimates of treatment effects. In addition, running sensitivity analyses found whether the results remained robust after excluding studies at high risk of bias or considering the alternative statistical model applied in the analysis.

Safety Profile and Recommendations: The combined efficacy data are analyzed for risk-benefit appraisal concerning the occurrence of adverse events. Formulation of recommendations about evidence-based regimens to be used and criteria for selecting patients based on synthesized data.

Conclusion

Magnesium sulfate (MgSO4) optimization could be used in pediatric patients for the management of acute exacerbation of asthma in children, pointing toward a highly promising direction for bettering clinical outcomes and reducing health burdens. This paper, therefore, forms the current state of the literature during original research endeavoring towards appraising the efficacy, safety considerations, and possible consequences of using MgSO4 as an adjuvant therapy in the management of pediatric asthma.

Thus, the literature review has been focused on different studies for the last ten years, which present a sustained interest in the exploration of MgSO4 as a therapeutic option to use in pediatric asthma exacerbations. Differences in sample size, treatment modalities, dosing protocols, and efficacy outcomes existed amongst these studies, and further studies are therefore necessary to fine-tune strategies of treatment and guidelines development.

However, despite this variability from the characteristics in each study, a common trend was noted to exist whereby the administration of MgSO4 seemed to be related to favorable outcomes—improved pulmonary function, faster correction of oxygen saturation, and rapid clinical improvement. Adverse events of such a profile remain dose-dependent, however; safety margins still call for close monitoring to avoid the risks.

Moreover, other treatment response factors, such as age, severity of asthma, and co-morbidities, make it of importance to evolve personalized treatment approaches depending on the profile of the individual patient. Addressing these and refining dosing regimens, health providers can optimize MgSO4 therapy to improve effectiveness while reducing adverse events.

The implication, therefore, of the optimized use of MgSO4 in the clinical management of pediatric asthma transcends from clinical implications to that of healthcare economics. Magnesium sulfate can lead, therefore, to improved treatment effectiveness with decreased complications, which will be useful for the more efficient use of resources and cost-containing in the health care systems. This underlines how evidence-based recommendations and personalized care approaches to optimizing the patient outcome must be clearly tracked through economic sustainability.

The conclusion relevant to academic writing synthesizes the key findings and the implications in order to give a clean integrative summary of the research conducted. This paper contributed to the body of knowledge through a structured literature review and an original research design in work relating to the management of pediatric asthma.

This research sets the stage for further studies that might refine treatment strategies for improved patient outcomes by setting the efficacy and safety considerations of MgSO4 therapy alongside personalized approaches to treatment. Further research should, therefore, be conducted on a relatively

larger scale, with robust outcome assessment and long-term follow-up, in order to continue investigating the use of MgSO4 in the management of pediatric asthma.

In so doing, the identified research gap and existing evidence can be built upon to further allow healthcare providers to enhance MgSO4 therapy in optimizing care and outcomes of pediatric patients with acute asthma exacerbations. Generally, optimizing the use of MgSO4 in pediatric asthma management bears great promise regarding improved clinical practice, enhanced patient outcomes, and potential reductions in healthcare burdens. Further study and evaluation to guide with evidence-based recommendations for the management of pediatric patients presenting with an acute exacerbation of asthma can improve the health of many children.

Limitations and Future Directions

Assessment of the heterogeneity between the studies is assessed by I^2 statistics and Cochran's Q tests.Source of heterogeneity examination with subgroup analyses and meta-regression. Account for variation in study design, outcome measures, and potential bias. Discussion of the need for standardized methodologies and increased sample sizes for deeper exploration. Future Research should look into long-term follow-up, measures of hard clinical endpoints, and study TNAs explicitly applied for each unique patient. The attitude also shifted, in that now, real-world evidence is emphasized with the focus being to replicate these findings within clinical practice through pragmatic trials.

References

1. Tesse, R., et al., Treating pediatric asthma according guidelines. 2018. 6: p. 234
2. Asher, M.I., et al., Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. 2006. 368(9537): p. 733-743.
3. Sullivan, P.W., et al., The national cost of asthma among school-aged children in the United States. 2017. 119(3): p. 246-252. e1.
4. Hughes, R., et al., Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. 2003. 361(9375): p. 2114-2117.
5. Amantéa, S.L., et al., Controversies in the pharmacological management of acute asthma in children. 2002. 78(Suppl 2): p. S151-60.
6. Cheuk, D., T. Chau, and S.J.A.o.d.i.c. Lee, A meta-analysis on intravenous magnesium sulphate for treating acute asthma. 2005. 90(1): p. 74-77.
7. Griffiths, B. and K.M.J.C.D.o.S.R. Kew, Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. 2016(4).
8. Johnson, M.D., et al., Intravenous magnesium in asthma pharmacotherapy: variability in use in the PECARN registry. 2020. 220: p. 165-174. e2.
9. Jones, L. and S.J.E.M.J. Goodacre, Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments. 2009. 26(11): p. 783-785.
10. Özdemir A, Doğruel D. Efficacy of Magnesium Sulfate Treatment in Children with Acute Asthma. Med Princ Pract. 2020;29(3):292-298. doi: 10.1159/000506595. Epub 2020 Feb 19. PMID: 32069472; PMCID: PMC7315220.
11. Aslan M, Çitlak HK, Topal E, Bağ HG, Kaplan F. Nebulize magnezyum sülfatın çocuklarda astım atakları üzerine etkisi. Anadolu KliniğI Tıp Bilimleri Dergisi. 2023;28(3):259-265. doi:10.21673/anadoluklin.1288549
12. Daengsuwan T, Watanatham S. A comparative pilot study of the efficacy and safety of nebulized magnesium sulfate and intravenous magnesium sulfate in children with severe acute asthma. Asian Pac J Allergy Immunol. 2017 Jun;35(2):108-112. doi: 10.12932/AP0780. PMID: 27996280.

13. Kokotajlo S, Degnan L, Meyers R, Siu A, Robinson C. Use of intravenous magnesium sulfate for the treatment of an acute asthma exacerbation in pediatric patients. J Pediatr Pharmacol Ther. 2014 Apr;19(2):91-7. doi: 10.5863/1551-6776-19.2.91. PMID: 25024668; PMCID: PMC4093670.
14. Schuh S, Freedman SB, Zemek R, et al. Association between intravenous magnesium therapy in the emergency department and subsequent hospitalization among pediatric patients with refractory acute asthma. JAMA Network Open. 2021;4(7):e2117542. doi:10.1001/jamanetworkopen.2021.17542
15. DeSanti, R.L., et al., The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting. 2018. 53(7): p. 866-871.
16. Nebulized Magnesium Sulphate as an Adjunct Therapy in the Management of Children Presenting with Acute Exacerbation of Asthma. Pakistan Journal of Medical & Health Sciences 12(2):673-674, vol. 12, no. 2, 2018, pjmhsonline.com/2018/april_june/pdf/554.pdf. Accessed 12 June 2024..
17. Graff DM, Stevenson MD, Berkenbosch JW. Safety of prolonged magnesium sulfate infusions during treatment for severe pediatric status asthmaticus. Pediatric Pulmonology. 2019;54(12):1941-1947. doi:10.1002/ppul.24499
18. Johnson, M.D., et al., Intravenous magnesium in asthma pharmacotherapy: variability in use in the PECARN registry. 2020. 220: p. 165-174. e2.
19. Schuh, S., et al., Effect of nebulized magnesium vs placebo added to albuterol on hospitalization among children with refractory acute asthma treated in the emergency department: a randomized clinical trial. 2020. 324(20): p. 2038-2047.
20. Wongwaree S, Daengsuwan T. Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation. Asian Pacific Journal of Allergy and Immunology. January 2019. doi:10.12932/ap-190717-0118
21. Ehsan S, Haresh S, Tarar SH. Effectiveness of Intravenous Magnesium Sulfate in Children Presenting to the Emergency Department with Acute Exacerbation of Asthma. Pakistan Journal of Health Sciences. February 2023:61-65. doi:10.54393/pjhs.v4i02.552
22. Kapuscinski CA, Stauber SD, Hutchinson DJ. Escalation in therapy based on intravenous magnesium sulfate dosing in pediatric patients with asthma exacerbations. the Journal of Pediatric Pharmacology and Therapeutics. 2020;25(4):314-319. doi:10.5863/1551-6776-25.4.314
23. DeLaroche AM, Mowbray FI, Bohsaghcheghazel M, Zalewski K, Obudzinski K. Early versus delayed administration of intravenous magnesium sulfate for pediatric asthma. the American Journal of Emergency Medicine. 2021;50:36-40. doi:10.1016/j.ajem.2021.07.003
24. Aziz DA, Sajjad MA, Iftikhar H. Clinical outcomes of children with acute asthma managed with intravenous magnesium sulphate outside intensive care setting. Monaldi Archives for Chest Disease Pulmonary Series/Monaldi Archives for Chest Disease/Monaldi Archives for Chest Disease Cardiac Series. September 2023. doi:10.4081/monaldi.2023.2664
25. Siddiqui H, Siddiqui SA, Yadav RK, et al. Nebulized Salbutamol with or without Magnesium Sulphate in the Management of Acute Asthma in Children in India: A Randomized Controlled Trial. Journal of Tropical Pediatrics. 2022;68(5). doi:10.1093/tropej/fmac070
26. PABON, H., G. MONEM, and N.J.P.e.c. KISSOON, Safety and efficacy of magnesium sulfate infusions in children with status asthmaticus. 1994. 10(4): p. 200-203.
27. Rovsing AH, Savran O, Ulrik CS. Magnesium sulfate treatment for acute severe asthma in adults-a systematic review and meta-analysis. Front Allergy. 2023 Jul 28;4:1211949. doi: 10.3389/falgy.2023.1211949. PMID: 37577333; PMCID: PMC10420062.